// App-Quantinova.ai

2995 : Using CRISPR/Cas9 to study resistance to glutaminase inhibition

Researchers

Presenter

  • Aleksandra M. Raczka

Principal Investigators

  • Paul A. Reynolds

Medical Centers

  • University of St. Andrews, St. Andrews, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Clear cell renal carcinoma

  • Solid malignancies

Biomarkers

  • BRCA1-associated protein 1

  • Polybromo 1

  • Glutamine

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Glutamine

  • CB-839

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved